Buscar
Mostrando ítems 1-4 de 4
PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
(MDPI, 2020)
info:eu-repo/semantics/article,
The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients ...
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
(MDPI, 2020)
info:eu-repo/semantics/article,
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ...
Profound reprogramming towards stemness in pancreatic cancer cells as adaptation to AKT inhibition
(MDPI, 2020)
info:eu-repo/semantics/article,
Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological ...
Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
(EMBO Press, 2020)
info:eu-repo/semantics/article,
The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ...